SCI时时刷

search
+
Effect of BI 1358894 on Cholecystokinin-Tetrapeptide (CCK-4)-Induced Anxiety, Panic Symptoms, and Stress Biomarkers: A Phase I Randomized Trial in Healthy Males
Effect of BI 1358894 on Cholecystokinin-Tetrapeptide (CCK-4)-Induced Anxiety, Panic Symptoms, and Stress Biomarkers: A Phase I Randomized Trial in Healthy Males
Depression, anxiety, and/or panic disorder are often comorbid and have a complex etiology mediated through the same neuron...
Thrombolysis with Recombinant Human Prourokinase 4.5–6 h After Acute Ischemic Stroke: A Phase IIa, Randomized, and Open-Label Multicenter Clinical Trial
Thrombolysis with Recombinant Human Prourokinase 4.5–6 h After Acute Ischemic Stroke: A Phase IIa, Randomized, and Open-Label Multicenter Clinical Trial
Ischemic stroke is a major cause of disability and death worldwide. A narrow therapeutic window profoundly constrained the...
Effects of Single and Multiple Ascending Doses of BI 1358894 in Healthy Male Volunteers on Safety, Tolerability and Pharmacokinetics: Two Phase I Partially Randomised Studies
Effects of Single and Multiple Ascending Doses of BI 1358894 in Healthy Male Volunteers on Safety, Tolerability and Pharmacokinetics: Two Phase I Partially Randomised Studies
The transient receptor potential canonical (TRPC) ion channels have been implicated in the pathophysiology of major depres...
Levetiracetam Interaction with Direct Oral Anticoagulants: A Pharmacovigilance Study
Levetiracetam Interaction with Direct Oral Anticoagulants: A Pharmacovigilance Study
Levetiracetam is widely used in post-stroke epilepsy. However, it is suspected to possess P-glycoprotein (P-gp) induction ...
Long-Term Treatment Over 52 Weeks with Monthly Fremanezumab in Drug-Resistant Migraine: A Prospective Multicenter Cohort Study
Long-Term Treatment Over 52 Weeks with Monthly Fremanezumab in Drug-Resistant Migraine: A Prospective Multicenter Cohort Study
Real-world studies on fremanezumab, an anti-calcitonin gene-related peptide monoclonal antibody for migraine prevention, a...
Context is a Critical for Psychoactive Drug Effects
Context is a Critical for Psychoactive Drug Effects
Pouyan N, Younesi Sisi F, Kargar A, Scheidegger M, McIntyre R, Morrow J. The effects of lysergic acid diethylamide (LSD) o...
The effects of Lysergic Acid Diethylamide (LSD) on the Positive Valence Systems: A Research Domain Criteria (RDoC)-Informed Systematic Review
The effects of Lysergic Acid Diethylamide (LSD) on the Positive Valence Systems: A Research Domain Criteria (RDoC)-Informed Systematic Review
The renewed interest in psychedelic research provides growing evidence of potentially unique effects on various aspects of...
Efficacy and Safety of MAO-B Inhibitors Safinamide and Zonisamide in Parkinson’s Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Efficacy and Safety of MAO-B Inhibitors Safinamide and Zonisamide in Parkinson’s Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
In Parkinson’s disease, safinamide and zonisamide are novel monoamine oxidase-B inhibitors with a dual mechanism of ...
Current Insights into Diagnosing and Treating Neurotuberculosis in Adults
Current Insights into Diagnosing and Treating Neurotuberculosis in Adults
Neurotuberculosis has the highest morbidity and mortality risk of all forms of extrapulmonary tuberculosis (TB). Early tre...
Trends and Differences in Status Epilepticus Treatment of Children and Adults Over 10 Years: A Comparative Study of Medical Records (2012–2021) from a University Hospital in Germany
Trends and Differences in Status Epilepticus Treatment of Children and Adults Over 10 Years: A Comparative Study of Medical Records (2012–2021) from a University Hospital in Germany
Over the last decade, significant advancements have been made in status epilepticus (SE) management, influenced by landmar...
A Prospective Longitudinal Study of the Effects of Eslicarbazepine Acetate Treatment on Bone Density and Metabolism in Patients with Focal-Onset Epilepsy
A Prospective Longitudinal Study of the Effects of Eslicarbazepine Acetate Treatment on Bone Density and Metabolism in Patients with Focal-Onset Epilepsy
Eslicarbazepine acetate (ESL) is a third-generation anti-seizure medication for patients with focal-onset epilepsy. There ...
A Semi-Naturalistic, Open-Label Trial Examining the Effect of Prescribed Medical Cannabis on Neurocognitive Performance
A Semi-Naturalistic, Open-Label Trial Examining the Effect of Prescribed Medical Cannabis on Neurocognitive Performance
Medical cannabis use is increasing in Australia and other jurisdictions, yet little is known about the effects of medical ...
Solriamfetol: A Review in Excessive Daytime Sleepiness Associated with Narcolepsy and Obstructive Sleep Apnoea
Solriamfetol: A Review in Excessive Daytime Sleepiness Associated with Narcolepsy and Obstructive Sleep Apnoea
Solriamfetol (SUNOSI®) is an oral selective dopamine and norepinephrine reuptake inhibitor approved in the EU and the...
Dextromethorphan-Bupropion for the Treatment of Depression: A Systematic Review of Efficacy and Safety in Clinical Trials
Dextromethorphan-Bupropion for the Treatment of Depression: A Systematic Review of Efficacy and Safety in Clinical Trials
A significant proportion of adults with major depressive disorder (MDD) do not respond to treatments which are currently u...
Stopping Disease-Modifying Treatments in Multiple Sclerosis: A Systematic Review and Meta-Analysis of Real-World Studies
Stopping Disease-Modifying Treatments in Multiple Sclerosis: A Systematic Review and Meta-Analysis of Real-World Studies
The question of whether multiple sclerosis requires life-long disease-modifying treatments (DMTs) remains unanswered. Some...
Authors’ Reply to Pande et al. Comment on “Extended-Release Viloxazine Compared to Atomoxetine for Attention Deficit Hyperactivity Disorder”
Authors’ Reply to Pande et al. Comment on “Extended-Release Viloxazine Compared to Atomoxetine for Attention Deficit Hyperactivity Disorder”
Funding This research did not receive any specific grant from fundi...
Comment on: “Extended‑Release Viloxazine Compared with Atomoxetine for Attention Deficit Hyperactivity Disorder”
Comment on: “Extended‑Release Viloxazine Compared with Atomoxetine for Attention Deficit Hyperactivity Disorder”
Funding No funding was received for the publication of this letter....
Lysergic Acid Diethylamide (LSD) for the Treatment of Anxiety Disorders: Preclinical and Clinical Evidence
Lysergic Acid Diethylamide (LSD) for the Treatment of Anxiety Disorders: Preclinical and Clinical Evidence
Anxiety disorders (ADs) represent the sixth leading cause of disability worldwide, resulting in a significant global econo...
New GABA-Targeting Therapies for the Treatment of Seizures and Epilepsy: I. Role of GABA as a Modulator of Seizure Activity and Recently Approved Medications Acting on the GABA System
New GABA-Targeting Therapies for the Treatment of Seizures and Epilepsy: I. Role of GABA as a Modulator of Seizure Activity and Recently Approved Medications Acting on the GABA System
γ-Aminobutyric acid (GABA) is the most prevalent inhibitory neurotransmitter in the mammalian brain and has been foun...
Over the Counter Supplements for Memory: A Review of Available Evidence
Over the Counter Supplements for Memory: A Review of Available Evidence
In 2021, the Global Brain Health Supplement Industry Market size was valued at US$7.6 billion. It is predicted to increase...
New GABA-Targeting Therapies for the Treatment of Seizures and Epilepsy: II. Treatments in Clinical Development
New GABA-Targeting Therapies for the Treatment of Seizures and Epilepsy: II. Treatments in Clinical Development
The inhibitory neurotransmitter γ-aminobutyric acid (GABA) plays an important role in the modulation of neuronal exci...
GABA-ergic Modulators: New Therapeutic Approaches to Premenstrual Dysphoric Disorder
GABA-ergic Modulators: New Therapeutic Approaches to Premenstrual Dysphoric Disorder
Premenstrual dysphoric disorder (PMDD) is characterized by the predictable onset of mood and physical symptoms secondary t...
The Utilization of Low Dose Naltrexone for Chronic Pain
The Utilization of Low Dose Naltrexone for Chronic Pain
Naltrexone is a mu-opioid receptor antagonist with a long half-life compared with naloxone. Both of these drugs, along wit...
Effectiveness and Safety of Switching from Oral Antipsychotics to Once-Monthly Paliperidone Palmitate (PP1M) in the Management of Schizophrenia: A Systematic Review and Meta-Analysis
Effectiveness and Safety of Switching from Oral Antipsychotics to Once-Monthly Paliperidone Palmitate (PP1M) in the Management of Schizophrenia: A Systematic Review and Meta-Analysis
Considering the improvement in adherence and convenience, once-monthly paliperidone palmitate (PP1M) has been increasingly...
Number, Duration, and Distribution of Wake Bouts in Patients with Insomnia Disorder: Effect of Daridorexant and Zolpidem
Number, Duration, and Distribution of Wake Bouts in Patients with Insomnia Disorder: Effect of Daridorexant and Zolpidem
Daridorexant, a dual orexin receptor antagonist approved in early 2022, reduces wake after sleep onset without reducing th...
Acute Valproate-Induced Encephalopathy in Status Epilepticus: A Registry-Based Assessment
Acute Valproate-Induced Encephalopathy in Status Epilepticus: A Registry-Based Assessment
Valproate-induced encephalopathy (VIE) affects between 0.1% and 2.5% of patients under long-term epilepsy treatment. Its f...
Amyloid-Lowering Monoclonal Antibodies for the Treatment of Early Alzheimer’s Disease
Amyloid-Lowering Monoclonal Antibodies for the Treatment of Early Alzheimer’s Disease
Alzheimer's disease (AD) is the leading cause of dementia worldwide. Numerous biomarker studies have clearly demonstra...
Increased Metabolic Potential, Efficacy, and Safety of Emerging Treatments in Schizophrenia
Increased Metabolic Potential, Efficacy, and Safety of Emerging Treatments in Schizophrenia
Patients with schizophrenia experience a broad range of detrimental health outcomes resulting from illness severity, heter...
Extended-Release Viloxazine Compared with Atomoxetine for Attention Deficit Hyperactivity Disorder
Extended-Release Viloxazine Compared with Atomoxetine for Attention Deficit Hyperactivity Disorder
In our outpatient pediatric and adult psychiatry centers, we reserve psychostimulants for predominantly inattentive attent...
Correction to: Rimegepant: A Review in the Acute Treatment and Preventive Treatment of Migraine
Correction to: Rimegepant: A Review in the Acute Treatment and Preventive Treatment of Migraine
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International ...
阅读更多
format_indent_increase